Valneva’s Covid-19 vaccine elicits a stronger immune response with far fewer side effects than the Oxford/AstraZeneca jab, according to trial results published a month after the UK terminated its €1.4bn deal with the French vaccine maker.
The first data from the phase 3 trial showed that participants who were given the Valneva vaccine had more neutralising antibodies than those who received the AstraZeneca shot.
Adam Finn, professor of paediatrics at the University of Bristol and trial chief investigator, said the immune responses were “both impressive and extremely encouraging”.
您已阅读22%（585字），剩余78%（2060字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。